Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Long-term, Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

NCT00504959 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00504959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00504959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Long-term, Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2007
Completion date
January 31, 2010
Enrollment
234 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

secondary to age-related macular degeneration (amd), subfoveal choroidal neovascularization (cnv)